

# ESMO Clinical Guidelines Sessions

## Introduction

Sunday 29 September 2019

ESMO 2019, Barcelona

**George Pentheroudakis**

# DISCLOSURE INFORMATION

George Pentheroudakis

Personal financial interests ( advisory services, speaking engagements): Amgen, Merck, Astra Zeneca, Roche, BMS, MSD, Lilly

Research support: Boehringer, Amgen, Merck, Astra Zeneca, Roche, Enorasis, BMS, Lilly


Institutional financial support for clinical trial research: Boehringer, Merck, Amgen, Astra Zeneca, Roche, Lilly, Abbvie, Debiopharm, Ipsen.

Non remunerated posts: Board, Society for Study of Clonal Heterogeneity of Neoplasia

# ESMO Guidelines Products

## ESMO Clinical Practice Guidelines

- Evidence-based, multidisciplinary guidelines
- Reviewed by independent experts and patients (ECPC)
- The standard for best practice
- Available on the ESMO and OncologyPRO websites: [esmo.org](http://esmo.org) / [oncologypro.org](http://oncologypro.org)
- Published in Annals of Oncology



# 2019: ESMO Clinical Practice Guidelines

## 6 New and updated titles:

- PAGA of ESMO NSCLC Guideline
- Renal Cell Carcinoma
- Early Breast Cancer
- Hereditary Gastrointestinal Cancers
- Non-small cell Metastatic Lung Cancer
- Thyroid cancer

## 5 Titles submitted to Annals of Oncology:

- Cutaneous Melanoma
- Marginal Zone Lymphomas
- PAGA of ESMO LA NSCLC Guideline
- PAGA of ESMO Early Breast Cancer Guideline
- PAGA of ESMO Hepatoma Guideline

# ESMO Guidelines Products

eUpdates: [www.esmo.org/Guidelines/Guidelines-News](http://www.esmo.org/Guidelines/Guidelines-News)

## 8 eUpdates:

- Grading and Treatment Recommendations for **Gastric Cancer**
- Updated Treatment Recommendations for **Cancer of the Prostate**
- Updated Treatment Recommendation and Algorithm for **Soft Tissue and Visceral Sarcomas**
- Grading and Treatment Recommendations for Cancer of the **Pancreas**
- Grading and Treatment Recommendations for **Hepatocellular Carcinoma**
- Updated Treatment Algorithm for Hepatocellular Carcinoma
- **Bladder Cancer** Treatment Recommendations
- **Early Colon Cancer** Treatment Recommendations

# THE LIVING GUIDELINE: A PILOT

Electronic updates are fully integrated into the parent Guideline

Newly published (18/SEPT/2019):

- Metastatic non-small cell lung cancer
- Both the updated (2019) and original (Annals 2018) versions are available on the ESMO website

<https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer>

The screenshot shows the ESMO website interface for the 'Metastatic Non-Small-Cell Lung Cancer' guideline. On the left is a navigation menu with categories like 'Guidelines News', 'ESMO Guidelines Slide Sets', and various cancer types. The 'Lung and Chest Tumours' category is highlighted. The main content area features the title 'Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up' in green. Below the title, it states the guidelines are based on recent studies and focus on treatment recommendations, including immunotherapy and targeted therapies. The update date is '18 September 2019'. A citation is provided: 'Ann Oncol (2018) 29 (suppl 4): iv192–iv237' and the URL 'https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer'. A 'Table of Contents' section lists topics such as 'Authors', 'Incidence and epidemiology', 'Diagnosis and pathology/molecular biology' (with sub-points for Table 1, Table 2, and Table 3), 'Staging and risk assessment' (with sub-points for Table 2 and Table 3), and 'Management of advanced/metastatic NSCLC' (with sub-points for Figure 1 and Figure 2).

ESMO / GUIDELINES / LUNG AND CHEST TUMOURS / Metastatic Non-Small-Cell Lung Cancer

**Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up**

The ESMO Clinical Practice Guidelines on Metastatic non-small cell lung cancer (NSCLC) are based on results from recent studies and analyses. The guidelines focus on treatment recommendations for the management of advanced/metastatic NSCLC, with an update on the role of immunotherapy and the use of targeted therapies for patients with tumours with specific gene mutations. Also covered are personalised medicine recommendations and new treatment algorithms.

Updated 18 September 2019

To cite this article, please include the original citation Ann Oncol (2018) 29 (suppl 4): iv192–iv237 and this online publication: <https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer>

» Table of Contents

- Authors
- Incidence and epidemiology
- Diagnosis and pathology/molecular biology
  - Table 1: A personalised medicine synopsis table for metastatic NSCLC
- Staging and risk assessment
  - Table 2: Staging and risk assessment
  - Table 3: Staging and stage grouping UICC TNM 8
- Management of advanced/metastatic NSCLC
  - Figure 1: Stage IV SCC
  - Figure 2: Stage IV NSCG, molecular tests negative

# ESMO Consensus Guidelines

- Derived from Consensus Conferences
- Pre-selected controversial questions addressed by multidisciplinary experts on specific tumour types

## Recently published:

- ESMO–ESGO Consensus Conference Recommendations on **Ovarian Cancer**

## Submitted to Ann Oncol:


- EAU–ESMO consensus statements on the management of advanced and variant **bladder cancer**
- Management of **Cardiac Disease** in Cancer Patients

## Manuscript in development:

- ESMO **Melanoma** Consensus Conference, September 2019

# ESMO Guidelines Slide Sets: 4

- **Set of 15-25 slides for each CPG title**
- Downloadable in PDF and PowerPoint from [esmo.org](http://esmo.org)
- Concise: algorithms and tables with key recommendations





# ESMO Guidelines web pages



Since 2016 there were over 1 million unique page views\* of ESMO Guidelines pages on the ESMO.org website each year

esmo.org pageviews	2011	2012	2013	2014	2015	2016	2017	2018	2019
Total for guidelines	89 530	100 738	394 889	738 260	893 000	1 052 185	1 377 993	1 582 195	<b>1 151 580</b> (to end Aug)

# WHAT'S NEW AT ESMO 2019?

**8 Pocket Guidelines titles distributed in the Society Village & Exhibition Hall  
(refer to the flyer in your delegate bag )**

- Breast Cancer
- Endocrine & NETs
- Leukaemia & Myeloma
- Lower Gastrointestinal Cancer
- Lung & Chest Tumours
- Supportive Care
- Upper Gastrointestinal Cancer
- Urogenital Tumours (2018)



# ESMO Guidelines Products

## -Guidelines Mobile and WEB App



Web App

Interactive App versions:

- Lung & Chest Tumours
- Upper Gastrointestinal cancers
- Lower gastrointestinal cancers
- Urogenital cancer
- Supportive care
- Lymphomas
- Breast cancer
- Leukaemia & Myeloma




Mobile App

PDF versions:

- Gynaecological Malignancies
- Melanoma
- Sarcoma & GIST
- Bone Health
- Head & Neck cancer

# ESMO Patient Guides

- Patient-education guides produced by ESMO
- Designed to assist patients, their relatives and caregivers to understand cancer and evaluate treatment options
- [esmo.org](http://esmo.org), downloadable in PDF format




# DON'T FORGET TO PICK UP YOUR COPIES



Delegate bag flyer, specifying where to collect each title @ ESMO 2019

- ESMO Pocket Guidelines
- Patient Guides series



# ESMO Clinical Practice Guidelines sessions

## Sunday 29 September 2019

### **Session 1: 09h45-11h45**

- Stage III ovarian cancer, *BRCA* wild type germline and somatic, platinum-sensitive relapse and molecular profiling (Irina Tsibulak, Mansoor Raza Mirza)
- Metastatic non-small cell lung cancer: Immunotherapy (Roberto Ferrara, Noemi Reguart)
- Metastatic Renal Cancer (Ricardo Pereira, Tom Powles)
- Stage III colorectal cancer: duration of therapy, molecular profiling (George Zarkavelis, Guillem Argiles)

### **Session 2: 14h45-16h45**

- Localised melanoma resected: adjuvant therapy followed by systemic relapse (Rebecca Lee, Olivier Michielin)
- Fatigue in cancer (Juliane Brandt, Fausto Roila)
- Advanced Hepatoma: Sequence of therapies (Daire Hanna, Arndt Vogel)
- Urothelial cancer: bladder-preserving strategies followed by systemic relapse (Bernadett Szabados, Shahrokh Shariat)